Overview

Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The durability of endovascular aneurysm repair (EVAR) has been limited by development of endoleaks which may be secondary to progressive aortic degeneration by matrix metalloproteases (MMP). Doxycycline is a known inhibitor of the MMP family of enzymes in aneurysms. The investigators propose a randomized, controlled trial of adjuvant doxycycline therapy with EVAR to determine its effects on re-intervention, aneurysm shrinkage and serum markers of aneurysmal degeneration.
Phase:
N/A
Details
Lead Sponsor:
Barnes-Jewish Hospital
The Foundation for Barnes-Jewish Hospital
Treatments:
Doxycycline